New data suggest more is better, but choices come with tradeoffs ...

Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...

A large South Korean cohort study has found no clear evidence that prenatal exposure to acid-suppressive medications ...

Researchers at Peter MacCallum Cancer Centre have developed a digital phenotype to assist with automatically identifying patients at risk of developing immune-related colitis.

Artificial Intelligence is transforming GI endoscopy by improving detection accuracy, enhancing diagnosis, and supporting ...

Once regarded as a disease affecting people over the age of 50, colorectal cancer is now rising at an alarming rate among ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...

A quiet layer of biology is beginning to change how health is understood, and it sits on the surface of nearly every cell in your body. Scientists now say these tiny sugar structures, once ignored, ...

From CBD shampoo and chocolate to skincare and even lubricants, you've no doubt seen CBD in just about every form imaginable over the past decade. But CBD oil – the original oral supplement taken as ...

Please provide your email address to receive an email when new articles are posted on . A post-hoc analysis of 11 trials found upadacitinib and infliximab had the highest symptom improvement rates at ...

By Puyaan Singh June 29 (Reuters) - Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, sending U.S.-listed shares of the ...